The principle of giving intensive polychemotherapy in the time between operation and irradiation was applied in a cooperative phase-2-study in children with medulloblastoma of the posterior fossa. A first evaluation of 33 of 47 registered patients was attempted after the study existing now for 1 year and 10 months. In the majority of patients the chemotherapy protocol could be fully realized without any deductions. Side effects including two therapy related fatalities were analysed. In all patients irradiation was not delayed and could be started about 11 weeks after operation and could be carried through without any major draw-backs. Analysis of survival can only be preliminary due to the short duration of the study, but patients' survival is compatible with other reported studies. The therapeutic principle presented here shall be compared in a randomized and extended fashion with a conventional therapeutic approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2008-1033814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology.
Radiat Oncol
January 2025
Department of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany.
Background: Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease.
View Article and Find Full Text PDFDemographic, medical, and neighborhood barriers to clinical neuropsychological services in pediatric medulloblastoma patients treated in the United States.
J Neurooncol
January 2025
Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.
Background: Medulloblastoma is the most commonly occurring malignant brain tumor of childhood. Treatment includes a combination of surgery, radiation therapy, and chemotherapy, all of which are associated with cognitive impairments. Despite appreciation of the value of neuropsychological evaluations to assess for cognitive impairments, there are barriers to these evaluations.
View Article and Find Full Text PDFProteome-Wide Identification and Comparison of Drug Pockets for Discovering New Drug Indications and Side Effects.
Molecules
January 2025
State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming 650500, China.
Drug development faces significant financial and time challenges, highlighting the need for more efficient strategies. This study evaluated the druggability of the entire human proteome using Fpocket. We identified 15,043 druggable pockets in 20,255 predicted protein structures, significantly expanding the estimated druggable proteome from 3000 to over 11,000 proteins.
View Article and Find Full Text PDFFerroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq.
Antioxidants (Basel)
January 2025
Energy & Memory, Brain Plasticity Unit, CNRS, ESPCI Paris, PSL Research University, F-75006 Paris, France.
Medulloblastoma (MB) is the most common malignant brain tumor in children, typically arising during infancy and childhood. Despite multimodal therapies achieving a response rate of 70% in children older than 3 years, treatment remains challenging. Ferroptosis, a form of regulated cell death, can be induced in medulloblastoma cells in vitro using erastin or RSL3.
View Article and Find Full Text PDFInternational benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study.
Lancet Child Adolesc Health
February 2025
Developmental Biology and Cancer Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK. Electronic address:
Background: International variation in childhood cancer survival might be explained by differences in stage at diagnosis, among other factors. As part of the BENCHISTA project, we aimed to assess geographical variation in tumour stage at diagnosis through the application, by population-based cancer registries working with clinicians, of the international consensus Toronto Childhood Cancer Stage Guidelines.
Methods: This population-based, retrospective cohort study involved 67 cancer registries from 23 European countries, Australia, Brazil, Japan, and Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!